Summary | |
---|---|
Symbol | DEFB114 |
Name | defensin, beta 114 |
Aliases | DEFB-14; DEFB14; beta-defensin 14; defensin, beta 14; Beta-defensin 114 |
Chromosomal Location | 6p12.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Secreted |
Domain |
PF13841 Beta defensin |
Function |
Has a salt-sensitive antimicrobial activity against Gram-negative bacteria, including E.coli, Gram-positive, including S.aureus, and fungi, including C.albicans. Binds to and neutralizes bacterial lipopolysaccharides (LPS), abolishing TNF production by macrophages challenged with LPS. Rescues the LPS-induced reduction of sperm motility in vitro and may protect from LPS-induced lethality. |
Biological Process |
GO:0002237 response to molecule of bacterial origin GO:0002831 regulation of response to biotic stimulus GO:0002832 negative regulation of response to biotic stimulus GO:0031663 lipopolysaccharide-mediated signaling pathway GO:0031664 regulation of lipopolysaccharide-mediated signaling pathway GO:0031665 negative regulation of lipopolysaccharide-mediated signaling pathway GO:0032102 negative regulation of response to external stimulus GO:0032496 response to lipopolysaccharide GO:0042742 defense response to bacterium GO:0043900 regulation of multi-organism process GO:0043901 negative regulation of multi-organism process GO:0071216 cellular response to biotic stimulus GO:0071219 cellular response to molecule of bacterial origin GO:0071222 cellular response to lipopolysaccharide GO:0071396 cellular response to lipid GO:0098542 defense response to other organism |
Molecular Function |
GO:0001530 lipopolysaccharide binding |
Cellular Component | - |
KEGG | - |
Reactome |
R-HSA-6803157: Antimicrobial peptides R-HSA-1461957: Beta defensins R-HSA-1461973: Defensins R-HSA-168256: Immune System R-HSA-168249: Innate Immune System |
Summary | |
---|---|
Symbol | DEFB114 |
Name | defensin, beta 114 |
Aliases | DEFB-14; DEFB14; beta-defensin 14; defensin, beta 14; Beta-defensin 114 |
Chromosomal Location | 6p12.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between DEFB114 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | DEFB114 |
Name | defensin, beta 114 |
Aliases | DEFB-14; DEFB14; beta-defensin 14; defensin, beta 14; Beta-defensin 114 |
Chromosomal Location | 6p12.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of DEFB114 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | DEFB114 |
Name | defensin, beta 114 |
Aliases | DEFB-14; DEFB14; beta-defensin 14; defensin, beta 14; Beta-defensin 114 |
Chromosomal Location | 6p12.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of DEFB114 in various data sets.
|
Points in the above scatter plot represent the mutation difference of DEFB114 in various data sets.
|
Summary | |
---|---|
Symbol | DEFB114 |
Name | defensin, beta 114 |
Aliases | DEFB-14; DEFB14; beta-defensin 14; defensin, beta 14; Beta-defensin 114 |
Chromosomal Location | 6p12.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DEFB114. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | DEFB114 |
Name | defensin, beta 114 |
Aliases | DEFB-14; DEFB14; beta-defensin 14; defensin, beta 14; Beta-defensin 114 |
Chromosomal Location | 6p12.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DEFB114. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DEFB114. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | DEFB114 |
Name | defensin, beta 114 |
Aliases | DEFB-14; DEFB14; beta-defensin 14; defensin, beta 14; Beta-defensin 114 |
Chromosomal Location | 6p12.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DEFB114. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | DEFB114 |
Name | defensin, beta 114 |
Aliases | DEFB-14; DEFB14; beta-defensin 14; defensin, beta 14; Beta-defensin 114 |
Chromosomal Location | 6p12.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of DEFB114 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | DEFB114 |
Name | defensin, beta 114 |
Aliases | DEFB-14; DEFB14; beta-defensin 14; defensin, beta 14; Beta-defensin 114 |
Chromosomal Location | 6p12.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between DEFB114 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |